Breast Ultrasound Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

Breast ultrasound uses high-frequency sound waves to visualize breast tissue and is widely deployed as an adjunct to mammography, particularly for women with dense breasts. The market encompasses conventional cart-based systems, automated breast ultrasound (ABUS) scanners, and handheld/point-of-care devices. With a 2025 valuation near USD 2.62 billion and an 11.4% CAGR, it is one of the faster-growing segments within medical imaging. Demand is reinforced by global breast cancer screening initiatives and the technology's safety profile, since ultrasound involves no ionizing radiation.

• •2025 market value: approximately USD 2.62 billion, projected CAGR of 11.4%.
• •Used primarily to supplement mammography, especially in dense-breast populations.
• •Covers conventional, automated (ABUS), and handheld device categories.

Rising breast cancer incidence worldwide is the single most powerful tailwind, alongside growing awareness of the limitations of mammography in dense breast tissue. Healthcare systems are expanding supplemental screening protocols that explicitly include ultrasound. Technological improvements, including AI-assisted lesion detection, elastography, and 3D/4D imaging, are improving diagnostic accuracy and clinician workflow, while portable and handheld devices are opening new care settings.

• •Dense-breast legislation in the U.S. and Europe is driving supplemental ultrasound screening.
• •AI-enabled image analysis and elastography are improving sensitivity and specificity.
• •Handheld and point-of-care devices are lowering cost barriers and expanding access.

By product, the market splits into conventional breast ultrasound (CBUS), automated breast ultrasound (ABUS), and handheld ultrasound systems, with ABUS gaining the most ground due to reproducibility and high-volume screening use. By technology, 2D ultrasound remains the workhorse, while 3D/4D and shear-wave elastography are the fastest-growing sub-segments. North America leads on revenue, supported by dense-breast notification laws and reimbursement coverage, while Asia-Pacific is the fastest-growing region as China, India, and Japan expand breast cancer screening infrastructure.

• •ABUS is the fastest-growing product category because it standardizes whole-bream imaging.
• •Hospitals dominate end-user share, followed by diagnostic imaging centers and ambulatory clinics.
• •Asia-Pacific is the highest-growth regional market; North America holds the largest revenue share.

What are the recent trends and outlook?

The next wave of growth is expected from AI-augmented interpretation, fusion imaging that combines ultrasound with mammography or MRI, and broader deployment of handheld devices in primary care and low-resource settings. Reimbursement expansion for supplemental ultrasound in dense-breast patients is a key swing factor in North America and Western Europe. Over the forecast period, the market is positioned to sustain low double-digit growth as screening volumes rise and technology becomes more accessible globally.

• •AI-driven computer-aided detection is becoming a standard purchasing criterion.
• •Fusion of ultrasound with mammography/MRI is improving biopsy targeting and surgical planning.
• •Reimbursement reform for supplemental screening in dense-breast patients remains the largest upside lever.